171 related articles for article (PubMed ID: 27941419)
1. Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Yoon S; Jeon SW; Ko YH; Patkar AA; Masand PS; Pae CU; Han C
J Clin Psychopharmacol; 2017 Feb; 37(1):46-53. PubMed ID: 27941419
[TBL] [Abstract][Full Text] [Related]
2. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Nomura I; Matsuda Y; Mishima K; Iwata N
Int J Neuropsychopharmacol; 2019 Nov; 22(11):698-709. PubMed ID: 31350882
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
Fava M; Ménard F; Davidsen CK; Baker RA
J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
[TBL] [Abstract][Full Text] [Related]
4. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.
Kato M; Shiosakai M; Kuwahara K; Iba K; Shimada Y; Saito M; Isogai Y; Sekine D; Aoki K; Koga N; Higuchi T
Psychiatry Clin Neurosci; 2024 Feb; 78(2):113-122. PubMed ID: 37933521
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
8. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
McIntyre RS; Weiller E; Zhang P; Weiss C
J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies.
Thase ME; Zhang P; Weiss C; Meehan SR; Hobart M
Expert Opin Pharmacother; 2019 Oct; 20(15):1907-1916. PubMed ID: 31290344
[No Abstract] [Full Text] [Related]
10. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
Hobart M; Skuban A; Zhang P; Augustine C; Brewer C; Hefting N; Sanchez R; McQuade RD
J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873953
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
Nelson JC; Weiller E; Zhang P; Weiss C; Hobart M
J Affect Disord; 2018 Feb; 227():103-108. PubMed ID: 29055257
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Antoun Reyad A; Girgis E; Mishriky R
Int Clin Psychopharmacol; 2020 May; 35(3):119-128. PubMed ID: 32141908
[TBL] [Abstract][Full Text] [Related]
15. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
16. Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies.
McIntyre RS; Bubolic S; Zhang Z; MacKenzie EM; Therrien F; Miguelez M; Boucher M
J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):133-140. PubMed ID: 38421922
[TBL] [Abstract][Full Text] [Related]
17. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
Weisler RH; Ota A; Tsuneyoshi K; Perry P; Weiller E; Baker RA; Sheehan DV
J Affect Disord; 2016 Nov; 204():40-7. PubMed ID: 27322768
[TBL] [Abstract][Full Text] [Related]
18. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4.
Therrien F; Ward C; Chokka P; Habert J; Ismail Z; McIntyre RS; MacKenzie EM
Can J Psychiatry; 2024 Jul; 69(7):513-523. PubMed ID: 38425284
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.
Hobart M; Zhang P; Weiss C; Meehan SR; Eriksson H
Int J Neuropsychopharmacol; 2019 Mar; 22(3):173-179. PubMed ID: 30508090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]